Biotech Values

[poorgradstudent]

I agree and I definitely painted with a wide brush there. I think it was one of the FDA transcripts with Bob Temple that influenced me. He waxed on and on about considerations for non-inferiority trials that made my head spin, especially when he started quoting patients numbers of about 1000 for appropriate trials.

I also think that it places a difficult marketing burden on a small biotech when they have to go out and compete with Lilly / Aventis et al based on non-inferiority rather than superiority.

fwiw...